Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma

Published:2019-10 Issue: Volume:58 Page:101814
ISSN:1094-5539
Container-title:Pulmonary Pharmacology & Therapeutics
language:en
Short-container-title:Pulmonary Pharmacology & Therapeutics

Author:

Bjermer Leif,Abbott-Banner Katharine,Newman Kenneth

Funder

Verona Pharma plc

David Young of Young Medical Communications and Consulting Ltd.

Verona Pharma plc.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Biochemistry, medical,Pulmonary and Respiratory Medicine

Reference20 articles.

1. Burden of asthma among patients adherent to ICS/LABA: a real-world study;Davis;J. Asthma,2019

2. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease;Banner;Br. J. Pharmacol.,2009

3. Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors;de Boer;Br. J. Pharmacol.,1992

4. Phosphodiesterase inhibitors in the treatment of inflammatory diseases;Page,2011

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ensifentrine approval: A milestone in the treatment of COPD;Pulmonary Pharmacology & Therapeutics;2024-12

2. Ensifentrine: First Approval;Drugs;2024-08-28

3. What role will ensifentrine play in the future treatment of chronic obstructive pulmonary disease patients? Implications from recent clinical trials;Immunotherapy;2023-12

4. PDE4 inhibitors for disease therapy: advances and future perspective;Future Medicinal Chemistry;2023-07

5. Current Perspectives of Pharmacotherapies for COPD;Respiratory Care;2023-06-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3